Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas

• Status: Recruiting
• Trial end date: 2022-02-28

Summary

The PIGLETS regimen was devised to replace the conventional SMILE regimen in management of extranodal NK/T cell lymphoma in our institution. It had been three years since the introduction of PIGLETS regimen in treatment of NK malignancies. The response rate is encouraging, with an overall response rate (ORR) of 90% in NK malignancies. Side effects are generally tolerable. The investigator therefore propose the use of PIGLETS on newly diagnosed or relapsed/refractory PTCLs.

• Phase: Phase 4

Details

• Lead Sponsor: The University of Hong Kong
• Treatments: Asparaginase; BB 1101; Cisplatin; Dexamethasone; Dexamethasone acetate; Etoposide; Etoposide phosphate; Gemcitabine; Ifosfamide; Isophosphamide mustard